PŘEHLEDOVÉ ČLÁNKY Lokalizovaná (unicentrická) forma Castlemanovy nemoci. Klinické projevy, diagnostika a léčba | 473 / Vnitř Lék 2021; 67(8): 465–473 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 22. Szturz P, Plank L Křístek J, et al. Castlemanova choroba v obrazech. Postgraduální me‑ dicína. 2014; 16 (1): 81–88. 23. Rovenský J, Lee B, Kozák I. Castlemanova choroba – multicentrická angiofolikulární lym‑ foidní hyperplazie Oftalmorevmatologie. První vydání. Praha : Galén, 2017. 2017, s. 221–226. 24. Penka L., Kala Z, Zetelová A, et al. Castleman’s disease - surgical treatment, case reports Rozhledy v chirurgii. 2016; 95 (12): 457–461. 25. Jakubec P, Kolek V, Jakubcová T, et al.Castlemanova nemoc - asymptomatický tumor me‑ diastina Studia pneumologica et phtiseologica. 2005; 65 (4):166–171. 26. Smolár M, Šutiak L, Mikolajčík A, et al. Lymfóm žalúdka ako príčina masívneho krvácania u pacienta s Castlemanovou chorobou. Rozhledy v chirurgii. 2010; 89 (5): 320–324. 27. Talat N, Belgaumkar AP Schulte KM. Surgery in Castleman’s disease: a systematic review of 404 published cases Ann Surg. 2012; 255(4):677–684). 28. FayandA, Boutboul D, Galicier L, et al. Epidemiology of Castleman disease associatedwith AA amyloidosis: description of 2 new cases and literature review. Amyloid.2019;26(4):197–202. 29. Raza HA, Nokes BT, Rosenthal AC, et al. Unicentric castleman disease complicated by pa‑ raneoplastic bronchiolitis obliterans and pemphigus.Respir Med Case Rep. 2018; 25:129–132. 30. Ohzono A,Sogame R, Li X, et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015;173(6):1447–1452. 31. Gerald W, Kostianovsky M, Rosai J. Development of vascular neoplasia in Castleman’s di‑ sease. Report of seven cases. Am J Surg Pathol. 1990;14(7):603–614. 32. Chang KC, Wang YC, Hung LY, et al. Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease.Mod Pathol. 2014; 27(6):823–831. 33. Cokelaere K, Debiec‑Rychter M, De Wolf‑Peeters C, et al. Hyaline vascular Castleman’s di‑ sease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of me‑ senchymal tumorigenesis. Am J Surg Pathol.2002;26(5):662–669. 34. Pauwels P, Dal Cin P, Vlasveld LT, et al. A chromosomal abnormality in hyaline vascu‑ lar Castleman’s disease: evidence for clonal proliferation of dysplastic stromal cells. Am J Surg Pathol. 2000;24(6):882–888. 35. Li Z, Lan X, Li C, et al. Recurrent PDGFRB mutations in unicentric Castleman disease. Leukemia. 2019; 33(4):1035–1038. 36. Dispenzieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of Castleman’s disea‑ se.Am J Hematol. 2012; 87(11):997–1002. 37. Talat N; Belgaumkar AP, Schulte KM. Surgery in Castleman’s disease: a systematic re‑ view of 404 published cases.Ann Surg.2012; 255(4):677–684. 38. Boutboul D, Fadlallah J, Chawki S, et al. Treatment and outcome of unicentric Cast‑ leman disease: a retrospective analysis of 71 cases. Br J Haematol. 2019;186(2):269–273 39. Mohan M, Meek JC, Meek ME, et al. Combinatorial treatment for unresectable unicen‑ tric Castleman disease. Eur J Haematol. 2021 Jul 9. doi: 10.1111/ejh.13685. 40. Bandera B, Ainsworth C, Shikle J, et al. Treatment of unicentric Castleman disease with neoadjuvant rituximab. Chest. 2010;138(5):1239–1241. 41. Baek HJ, Kook H, Han DK, et al. Unicentric Castleman disease relapsed after rituximab ‑CHOP chemotherapy or radiation therapy in an adolescent. J Pediatr Hematol Oncol. 2012; 34(5): e206–8. 42. Abid MB, Peck R, Abid MA, et al. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease? Hematol Oncol. 2018;36(1):320–323. 43. Fitzpatrick PJ, Brown TC. Angiofollicular lymph node hyperplasia. Can Med Assoc J. 1968;99(25):1259–1262. [PMC free article] [PubMed]. 44. Nordstrom DG, Tewfik HH, Latourette HB. Plasma cell giant lymph node hyperplasia responding to radiation therapy. AJR Am J Roentgenol. 1978;130(1):169–171. 45. Stokes SH, Griffith RC, Thomas PR. Angiofollicular lymph node hyperplasia (Cas‑ tleman’s disease) associated with vertebral destruction. Cancer. 1985;56(4):876–879. 46. Weisenburger DD, DeGowin RL, Gibson P, Armitage JO. Remission of giant lymph node hyperplasia with anemia after radiotherapy. Cancer. 1979;44(2):457–462. 47. Massey GV, Kornstein MJ, Wahl D, Huang XL, McCrady CW, Carchman RA. Angiofo‑ llicular lymph node hyperplasia (Castleman’s disease) in an adolescent female. Clini‑ cal and immunologic findings. Cancer. 1991;68(6):1365–1372. 48. Veldhuis GJ, van der Leest AH, de Wolf JT, de Vries EG, Vellenga E. A case of localized Castleman’s disease with systemic involvement: treatment and pathogenetic aspects. Ann Hematol. 1996;73(1):47–50. [PubMed] 49. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multi‑ centric Castleman’s disease: a report of 16 cases and a review of the literature. Can‑ cer. 1999;85(3):706–717. 50. Chronowski G M, Ha C S, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy Cancer 2001;92 (3): 670–676. 51. Neuhof D, Debus J. Outcome and late complications of radiotherapy in patients with unicentric Castleman disease. Acta Oncol. 2006;45(8):1126–1131. 52. Li YM, Liu PH, Zhang YH, et al. Radiotherapy of unicentric mediastinal Castleman’s di‑ sease. Chin J Cancer. 2011;30(5): 351–356. 53. Matthiesen C, Ramgopol R, Seavey J, et al. Intensity modulated radiation therapy (IMRT) for the treatment of unicentric Castlemans disease: a case report and review of the use of radiotherapy in the literature. Radiol Oncol 2012;46(3):265–270. 54. Miranda FA, Faria VH, Arruda GV, Silva LG. Radiation therapy in the treatment of uni‑ centric Castleman’s disease. J Bras Pneumol. 2013;39(1):116–118. 55. Oksenhendler E, Boutboul D, Fajgenbaum D, et al. The full spectrum of Castle‑ man disease: 273 patients studied over 20 years. Br J Haematol. 2018;180(2):206–216. 56. Boutboul D, Fadlallah J, Chawki S, et al. Treatment and outcome of unicentric Cast‑ leman disease: a retrospective analysis of 71 cases. Br J Haematol. 2019;186(2):269–273 57. Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with pa‑ raneoplastic autoimmune multi‑organ syndrome. Respirology. 2009;14(1):129–133. 58. Dong Y, Wang M, Nong L, et al. Clinical and laboratory characterization of 114 ca‑ ses of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol. 2015;169(6):834–842. 59. Jain P, Milgrom SA, Patel KP, et al. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol. 2017;178(3):403–412. CVD ONLINE Rádi bychom vás pozvali na stránky akreditovaného kurzu chronického žilního onemocnění, kde kromě klasického e-learningu najdete také příběh typické pacientky, se kterou společně procházíme léčbou. www.cvdonline.cz AKRED I TACE ČLK 1 7 BODŮ Multioborový akreditovaný kurz a průvodce léčbou chronického žilního onemocnění
RkJQdWJsaXNoZXIy NDA4Mjc=